About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Gt(ROSA)26Sortm2(cre/ERT2)Brn
targeted mutation 2, Anton Berns
MGI:3764519
Summary 23 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Pknox1tm2.1Fbla/Pknox1tm2.1Fbla
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd MGI:5469881
cn2
Bcl11atm2.1Peli/Bcl11atm2.1Peli
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv MGI:5475382
cn3
Bcl11atm2.1Peli/Bcl11atm2.1Peli
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv MGI:5475383
cn4
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ MGI:4452396
cn5
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6 MGI:5447637
cn6
Ptch1tm1Hahn/Ptch1+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6 MGI:5447639
cn7
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 MGI:3764626
cn8
Ptch1tm1Hahn/Ptch1+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 MGI:5447638
cn9
Foxn1tm1.1Cbln/Foxn1tm1Tbo
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 MGI:5297816
cn10
Prmt5tm2c(EUCOMM)Wtsi/Prmt5tm2c(EUCOMM)Wtsi
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/SvlmJ * C57BL/6Brd * C57BL/6N * SJL MGI:5546603
cn11
Nle1tm1Cba/Nle1tm1.1Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas MGI:5553372
cn12
Nle1tm1Cba/Nle1tm1.1Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S2/SvPas MGI:5553371
cn13
Zfp830tm2.1Cota/Zfp830tm2.2Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/?
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6 MGI:4950720
cn14
Hdac1tm1.1Mrl/Hdac1tm1.1Mrl
Hdac2tm1.1Rdp/Hdac2tm1.1Rdp
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 MGI:5494632
cn15
Gas2l3tm1c(EUCOMM)Hmgu/Gas2l3tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N MGI:6116291
cn16
Odad3tm1c(EUCOMM)Hmgu/Odad3tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N MGI:6360704
cn17
Bcl11btm1Peli/Bcl11btm1Peli
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J MGI:4818786
cn18
Dll4tm2.1Vlcg/Dll4+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac MGI:5302388
cn19
Rag1tm1.1Sadu/Rag1tm1.1Sadu
Trdctm1Mal/Trdctm1Mal
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * BALB/c * C57BL/6 MGI:5438822
cn20
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(RasE)290Biat/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 MGI:5770438
cn21
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Ptentm2Mak/Ptentm2Mak
Tg(RasE)290Biat/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 MGI:5770439
cn22
Gt(ROSA)26Sortm2(cre/ERT2)Brn/0
Tg(Sftpc-Grem1)105Mmyl/0
involves: 129P2/OlaHsd * C57BL/6N MGI:5707181
cn23
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(GFP/KRAS2/ALPP)1Brn/0
involves: 129P2/OlaHsd * FVB/N MGI:3765975


Genotype
MGI:5469881
cn1
Allelic
Composition
Pknox1tm2.1Fbla/Pknox1tm2.1Fbla
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Pknox1tm2.1Fbla mutation (0 available); any Pknox1 mutation (90 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• in tamoxifen-treated mice
• in tamoxifen-treated mice

immune system
• in tamoxifen-treated mice
• in tamoxifen-treated mice




Genotype
MGI:5475382
cn2
Allelic
Composition
Bcl11atm2.1Peli/Bcl11atm2.1Peli
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl11atm2.1Peli mutation (0 available); any Bcl11a mutation (44 available)
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• in pro-B, pre-B and immature B cells of tamoxifen-treated mice
• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2
• in the bone marrow of tamoxifen-treated mice
• few early T cell progenitors in the thymus of tamoxifen-treated mice
• in tamoxifen-treated mice
• reduced 7-fold in tamoxifen-treated mice
• in the bone marrow of tamoxifen-treated mice
• however, the number of B cells in the spleen, lymph node and peripheral blood is normal
• to one-fifth of wild-type levels in the bone marrow of tamoxifen-treated mice
• in the bone marrow of tamoxifen-treated mice
• reduced LSK and lymphoid-primed multipotent progenitors in tamoxifen-treated mice
• tamoxifen-treated LSK cells exhibit a complete loss of lymphoid development

cellular
• in pro-B, pre-B and immature B cells of tamoxifen-treated mice
• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2

immune system
• in pro-B, pre-B and immature B cells of tamoxifen-treated mice
• however, apoptosis is rescued by exogenous Bcl2 or Mdm2 and Bcl2
• complete loss of lymphoid development in tamoxifen-treated bone marrow cells is cell autonomous
• in the bone marrow of tamoxifen-treated mice
• few early T cell progenitors in the thymus of tamoxifen-treated mice
• in tamoxifen-treated mice
• in the bone marrow of tamoxifen-treated mice
• however, the number of B cells in the spleen, lymph node and peripheral blood is normal
• to one-fifth of wild-type levels in the bone marrow of tamoxifen-treated mice
• in the bone marrow of tamoxifen-treated mice

endocrine/exocrine glands
• in tamoxifen-treated mice




Genotype
MGI:5475383
cn3
Allelic
Composition
Bcl11atm2.1Peli/Bcl11atm2.1Peli
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl11atm2.1Peli mutation (0 available); any Bcl11a mutation (44 available)
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (240 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• early B cell development is rescued in tamoxifen treated mice
• reduced LSK and lymphoid-primed multipotent progenitors in tamoxifen-treated mice
• tamoxifen-treated LSK cells exhibit a complete loss of lymphoid development

immune system
N
• early B cell development is rescued in tamoxifen treated mice




Genotype
MGI:4452396
cn4
Allelic
Composition
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Ptch1tm1Hahn mutation (1 available); any Ptch1 mutation (115 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• after 45 days of tamoxifen treatment, mice exhibit visible tumors in the tails and ears unlike similarly treated wild-type mice
• 90 days after tamoxifen treatment, mice exhibit fully developed basal cell carcinomas (BCC) that are not invasive or aggressive over time
• BCCs likely originate from the outer root sheath of the hair follicle based on antibody staining
• after 200 days of tamoxifen treatment tumors are smaller than fully developed basal cell carcinomas and exhibit decreased proliferation indicating regression

integument
• after 45 days of tamoxifen treatment, mice exhibit visible tumors in the tails and ears unlike similarly treated wild-type mice
• 90 days after tamoxifen treatment, mice exhibit fully developed basal cell carcinomas (BCC) that are not invasive or aggressive over time
• BCCs likely originate from the outer root sheath of the hair follicle based on antibody staining

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
basal cell carcinoma DOID:2513 J:158915




Genotype
MGI:5447637
cn5
Allelic
Composition
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Ptch1tm1Hahn mutation (1 available); any Ptch1 mutation (115 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 205 days
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks and 1 umol CTX is 171 days compared with 338 days for control mice
• median survival in mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks is 160 days compared with 228 days for control mice

neoplasm
• mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks or intramuscular treatment 50 ug tamoxifen at 2 weeks exhibit rare follicular tumors on the trunk and paws
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice

integument
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice




Genotype
MGI:5447639
cn6
Allelic
Composition
Ptch1tm1Hahn/Ptch1+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Ptch1tm1Hahn mutation (1 available); any Ptch1 mutation (115 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 326 days




Genotype
MGI:3764626
cn7
Allelic
Composition
Ptch1tm1Hahn/Ptch1tm1Hahn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Ptch1tm1Hahn mutation (1 available); any Ptch1 mutation (115 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks is 205 days
• median survival in mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks and 1 umol CTX is 171 days compared with 338 days for control mice
• median survival in mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks is 160 days compared with 228 days for control mice

immune system
• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla
• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold
• 19 days after the first injection of tamoxifen, the DN1 population is overrepresented while the DN2 and DN3 populations are underrepresented
• however, the DN4 population is stable after tamoxifen treatment
• 19 days after the first injection of tamoxifen, the relative number of immature double positive cells is increased compared to in Ptch1tm1Jwnd control mice
• following treatment with tamoxifen, the number of neutrophilic granulocytes is increased compared to in Ptch1tm1Jwnd control mice
• following treatment with tamoxifen, circulating B220high, IgD+ B cells are increased compared to in Ptch1tm1Jwnd control mice
• at day15 through 19 after the first injection of tamoxifen, mature B cells are overrepresented in the spleen compared to in Ptch1tm1Jwnd control mice
• 19 days after the first injection of tamoxifen, the relative number of mature single positive cells is increased compared to in Ptch1tm1Jwnd control mice
• following treatment with tamoxifen, total lymphocyte fraction in the bone marrow is only slightly decreased compared to in Ptch1tm1Jwnd control mice
• 19 days after the first injection of tamoxifen, the number of double positive cells is almost depleted compared to in Ptch1tm1Jwnd control mice
• at day15 through 19 after the first injection of tamoxifen, the number of B220+ B cells in the spleen is reduced (4.71+/-2.33% compared to 13.98+/-3.74% in Ptch1tm1Jwnd control mice)
• following treatment with tamoxifen, CD43+ B cells are almost completely absent and fraction I and II immature B cells are decreased in the bone marrow compared to in Ptch1tm1Jwnd control mice
• at day15 through 19 after the first injection of tamoxifen, the number of T1 transitional B cells is reduced in the spleen compared to in Ptch1tm1Jwnd control mice
• following treatment with tamoxifen, bone marrow B220low pre-B cells are lower than in Ptch1tm1Jwnd control mice

neoplasm
• mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks or intramuscular treatment 50 ug tamoxifen at 2 weeks exhibit rare follicular tumors on the trunk and paws
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice

integument
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment with 100 ug tamoxifen and 1 umol CTX at 6 to 8 weeks unlike control mice
• in 10 of 10 mice subjected to intramuscular treatment 50 ug tamoxifen at 2 weeks unlike control mice

hematopoietic system
• however, granulocyte-macrophage lineage specification is normal following treatment with tamoxifen
• following treatment with tamoxifen, the Lin-c-kithighSca-1high population is increased while the population of Lin-c-kitlowSca-1low are underrepresented compared to in Ptch1tm1Jwnd control mice
• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla
• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold
• 19 days after the first injection of tamoxifen, the DN1 population is overrepresented while the DN2 and DN3 populations are underrepresented
• however, the DN4 population is stable after tamoxifen treatment
• 19 days after the first injection of tamoxifen, the relative number of immature double positive cells is increased compared to in Ptch1tm1Jwnd control mice
• following treatment with tamoxifen, the number of neutrophilic granulocytes is increased compared to in Ptch1tm1Jwnd control mice
• following treatment with tamoxifen, circulating B220high, IgD+ B cells are increased compared to in Ptch1tm1Jwnd control mice
• at day15 through 19 after the first injection of tamoxifen, mature B cells are overrepresented in the spleen compared to in Ptch1tm1Jwnd control mice
• 19 days after the first injection of tamoxifen, the relative number of mature single positive cells is increased compared to in Ptch1tm1Jwnd control mice
• following treatment with tamoxifen, total lymphocyte fraction in the bone marrow is only slightly decreased compared to in Ptch1tm1Jwnd control mice
• 19 days after the first injection of tamoxifen, the number of double positive cells is almost depleted compared to in Ptch1tm1Jwnd control mice
• at day15 through 19 after the first injection of tamoxifen, the number of B220+ B cells in the spleen is reduced (4.71+/-2.33% compared to 13.98+/-3.74% in Ptch1tm1Jwnd control mice)
• following treatment with tamoxifen, CD43+ B cells are almost completely absent and fraction I and II immature B cells are decreased in the bone marrow compared to in Ptch1tm1Jwnd control mice
• at day15 through 19 after the first injection of tamoxifen, the number of T1 transitional B cells is reduced in the spleen compared to in Ptch1tm1Jwnd control mice
• following treatment with tamoxifen, bone marrow B220low pre-B cells are lower than in Ptch1tm1Jwnd control mice

endocrine/exocrine glands
• 19 days after the first injection of tamoxifen, the thymus has lost its regular morphology and the cortex is no longer distinguishable from the medulla
• 15 days after the first injection of tamoxifen, thymus cellularity is decreased by 13-fold




Genotype
MGI:5447638
cn8
Allelic
Composition
Ptch1tm1Hahn/Ptch1+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Ptch1tm1Hahn mutation (1 available); any Ptch1 mutation (115 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• median survival in mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks is 376 days compared with 441 days for control mice

neoplasm
• hamartomatous gastrointestinal cystic tumors in 4 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice
• in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice

integument
• epidermal cysts in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice

growth/size/body
• epidermal cysts in 1 of 32 mice subjected to intraperitoneal treatment with 5 mg tamoxifen at 8 weeks unlike control mice




Genotype
MGI:5297816
cn9
Allelic
Composition
Foxn1tm1.1Cbln/Foxn1tm1Tbo
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Foxn1tm1.1Cbln mutation (0 available); any Foxn1 mutation (106 available)
Foxn1tm1Tbo mutation (0 available); any Foxn1 mutation (106 available)
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• restoration of normal thymus if cre induction with tamoxiphen occurs before 4 months of age




Genotype
MGI:5546603
cn10
Allelic
Composition
Prmt5tm2c(EUCOMM)Wtsi/Prmt5tm2c(EUCOMM)Wtsi
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S1/SvlmJ * C57BL/6Brd * C57BL/6N * SJL
Cell Lines EPD0160_2_A08
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Prmt5tm2c(EUCOMM)Wtsi mutation (1 available); any Prmt5 mutation (45 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
embryo
• at E15.5 following tamoxifen treatment at E10.5
• at E15.5 following tamoxifen treatment at E10.5

integument
• at E15.5 following tamoxifen treatment at E10.5

growth/size/body
• at E15.5 following tamoxifen treatment at E10.5
• at E15.5 following tamoxifen treatment at E10.5




Genotype
MGI:5553372
cn11
Allelic
Composition
Nle1tm1Cba/Nle1tm1.1Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Trp53tm1Tyj/Trp53tm1Tyj
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Nle1tm1.1Cota mutation (0 available); any Nle1 mutation (27 available)
Nle1tm1Cba mutation (0 available); any Nle1 mutation (27 available)
Trp53tm1Tyj mutation (12 available); any Trp53 mutation (240 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• tamoxifen-treated mice exhibit rescued total bone marrow and LSK cells




Genotype
MGI:5553371
cn12
Allelic
Composition
Nle1tm1Cba/Nle1tm1.1Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Nle1tm1.1Cota mutation (0 available); any Nle1 mutation (27 available)
Nle1tm1Cba mutation (0 available); any Nle1 mutation (27 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Severe hypocellularity in Nle1tm1Cba/Nle1tm1.1Cota Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+ bone marrow, with capillaries saturated with erythrocytes

mortality/aging
• mice die 10 to 13 days after tamoxifen treatment

immune system
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• defects in secondary lymphoid organs in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice

digestive/alimentary system
• 7 to 9 days after tamoxifen treatment

cellular
• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice

hematopoietic system
N
• hematopoietic stem cell mobilization occurs normally in tamoxifen-treated mice
• in tamoxifen-treated mice
• tamoxifen-treated mice exhibit cell autonomous defects in hematopoiesis
• in tamoxifen-treated mice
• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice
• severe in tamoxifen-treated mice
• decreased in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• reduced hematopoietic stem cell and multipotent progenitor quiescence in tamoxifen-treated mice

endocrine/exocrine glands
• in tamoxifen-treated mice




Genotype
MGI:4950720
cn13
Allelic
Composition
Zfp830tm2.1Cota/Zfp830tm2.2Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/?
Genetic
Background
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Zfp830tm2.1Cota mutation (0 available); any Zfp830 mutation (14 available)
Zfp830tm2.2Cota mutation (0 available); any Zfp830 mutation (14 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• in tamoxifen-treated fibroblasts
• proliferation of mouse embryonic fibroblasts is arrested 24 hours after tamoxifen-treatment unlike in control cells




Genotype
MGI:5494632
cn14
Allelic
Composition
Hdac1tm1.1Mrl/Hdac1tm1.1Mrl
Hdac2tm1.1Rdp/Hdac2tm1.1Rdp
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Hdac1tm1.1Mrl mutation (0 available); any Hdac1 mutation (38 available)
Hdac2tm1.1Rdp mutation (1 available); any Hdac2 mutation (40 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• tamoxifen-treated mouse embryonic fibroblasts exhibit a 2-fold reduction in S-phase cells and an increase in G1 phase cell compared with control cells
• tamoxifen-treated mouse embryonic fibroblasts exhibit growth arrest compared with control cells
• in tamoxifen-treated mouse embryonic fibroblasts




Genotype
MGI:6116291
cn15
Allelic
Composition
Gas2l3tm1c(EUCOMM)Hmgu/Gas2l3tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gas2l3tm1c(EUCOMM)Hmgu mutation (0 available); any Gas2l3 mutation (72 available)
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
N
• no increase in heart weight, no dilation, and no fibrosis when tamoxifen is used to induce loss of expression in neonatal mice unlike when expression is absent in embryonic stages
• in cultured cardiomyocytes after tamoxifen induction 22% become binucleated while very few cells were binucleate before tamoxifen exposure
• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission

cellular
• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission
• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission

muscle
• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission




Genotype
MGI:6360704
cn16
Allelic
Composition
Odad3tm1c(EUCOMM)Hmgu/Odad3tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Odad3tm1c(EUCOMM)Hmgu mutation (0 available); any Odad3 mutation (27 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• in tamoxifen-treated mice
• in tamoxifen-treated mice

cellular
• in tamoxifen-treated mice
• in tamoxifen-treated mice




Genotype
MGI:4818786
cn17
Allelic
Composition
Bcl11btm1Peli/Bcl11btm1Peli
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bcl11btm1Peli mutation (0 available); any Bcl11b mutation (46 available)
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• cultured tamoxifen-treated DN1, DN2, and DN3 thymocytes differentiate into natural killer-like cells and kill stromal feeder cells unlike similarly treated wild-type thymocytes
• cultured spleen and thymus cells treated with tamoxifen exhibit differentiation into induced T to natural killer cells (ITNK) unlike cells from similarly treated wild-type cells
• tamoxifen-treated thymocytes transplanted into Rag2 Il2rg null mice exhibit an increase in ITNK cells compared with mice transplanted with similarly treated wild-type mice

neoplasm
• reprogrammed induced T to natural killer cells (ITNK) transplanted into Rag2 Il2rg null suppress metastasis of transplanted B16F10 melanoma cells

hematopoietic system
• cultured tamoxifen-treated DN1, DN2, and DN3 thymocytes differentiate into natural killer-like cells and kill stromal feeder cells unlike similarly treated wild-type thymocytes
• cultured spleen and thymus cells treated with tamoxifen exhibit differentiation into induced T to natural killer cells (ITNK) unlike cells from similarly treated wild-type cells
• tamoxifen-treated thymocytes transplanted into Rag2 Il2rg null mice exhibit an increase in ITNK cells compared with mice transplanted with similarly treated wild-type mice




Genotype
MGI:5302388
cn18
Allelic
Composition
Dll4tm2.1Vlcg/Dll4+
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dll4tm2.1Vlcg mutation (0 available); any Dll4 mutation (27 available)
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• retinal capillaries from tamoxifen-treated mice are more resistant to oxygen-induced vaso-obliteration compared with control capillaries
• tamoxifen-treated mice exhibit reduced capillary regression during normal developmental capillary remodeling compared with control mice

vision/eye
• retinal capillaries from tamoxifen-treated mice are more resistant to oxygen-induced vaso-obliteration compared with control capillaries

cellular
• tamoxifen-treated mice exhibit reduced capillary regression during normal developmental capillary remodeling compared with control mice




Genotype
MGI:5438822
cn19
Allelic
Composition
Rag1tm1.1Sadu/Rag1tm1.1Sadu
Trdctm1Mal/Trdctm1Mal
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * BALB/c * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Rag1tm1.1Sadu mutation (0 available); any Rag1 mutation (123 available)
Trdctm1Mal mutation (1 available); any Trdc mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• in un-induced mice
• however, tamoxifen induction rescues thymus size
• Vgamma4+ gamma delta T cells in the peripheral lymph nodes, spleen, lung and liver despite tamoxifen treatment of adult mice
• absent IL17+ cells despite tamoxifen treatment of adult mice
• Vgamma1+ gamma delta T cells in the spleen, lung and liver despite tamoxifen treatment of adult mice

hematopoietic system
• in un-induced mice
• however, tamoxifen induction rescues thymus size
• Vgamma4+ gamma delta T cells in the peripheral lymph nodes, spleen, lung and liver despite tamoxifen treatment of adult mice
• absent IL17+ cells despite tamoxifen treatment of adult mice
• Vgamma1+ gamma delta T cells in the spleen, lung and liver despite tamoxifen treatment of adult mice

endocrine/exocrine glands
• in un-induced mice
• however, tamoxifen induction rescues thymus size




Genotype
MGI:5770438
cn20
Allelic
Composition
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(RasE)290Biat/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Tg(RasE)290Biat mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• about 80% of tamoxifen-injected mice develop tumors in the skin which immunohistochemistry suggests are skin-appendage tumors derived from sebaceous glands
• skin-appendage tumors develop when 4-OH tamoxifen is applied atopically onto the back of the skin; 98.3% of tumors show simultaneous activation of the three alleles
• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection
• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas
• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas
• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection
• lung tumors of tamoxifen treated mice are adenocarcinomas

endocrine/exocrine glands
• about 80% of tamoxifen-injected mice develop tumors in the skin which immunohistochemistry suggests are skin-appendage tumors derived from sebaceous glands
• skin-appendage tumors develop when 4-OH tamoxifen is applied atopically onto the back of the skin; 98.3% of tumors show simultaneous activation of the three alleles
• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection
• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas
• pancreatic tumors of tamoxifen treated mice are intraepithelial neoplasias or pancreatic ductal adenocarcinomas

respiratory system
• 100% of mice develop lung and pancreatic cancers at between 8 and 12 weeks after tamoxifen injection
• lung tumors of tamoxifen treated mice are adenocarcinomas

integument
• about 80% of tamoxifen-injected mice develop tumors in the skin which immunohistochemistry suggests are skin-appendage tumors derived from sebaceous glands
• skin-appendage tumors develop when 4-OH tamoxifen is applied atopically onto the back of the skin; 98.3% of tumors show simultaneous activation of the three alleles




Genotype
MGI:5770439
cn21
Allelic
Composition
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Ptentm2Mak/Ptentm2Mak
Tg(RasE)290Biat/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Ptentm2Mak mutation (4 available); any Pten mutation (88 available)
Tg(RasE)290Biat mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• tamoxifen treated mice exhibit shortened lifespan

neoplasm
• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics
• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics

endocrine/exocrine glands
• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics

respiratory system
• tamoxifen treated mice exhibit accelerated formation of lung and pancreatic tumors compared to single Tg(RasE)290Biat transgenics




Genotype
MGI:5707181
cn22
Allelic
Composition
Gt(ROSA)26Sortm2(cre/ERT2)Brn/0
Tg(Sftpc-Grem1)105Mmyl/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Tg(Sftpc-Grem1)105Mmyl mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• following exposure to silica, the lung tissue of these mice exhibits significantly less inflammatory cell infiltration than that of wild-type mice.

respiratory system
• following exposure to silica, the lung tissue of these mice exhibits significantly less inflammatory cell infiltration than that of wild-type mice.
• at 6 months of age, these mice may exhibit some alveolar space enlargement
• at 6 months of age, these mice exhibit mild septal thickening
• the lungs of these mice exhibit no histologically apparent alterations in fibrosis following exposure to silica




Genotype
MGI:3765975
cn23
Allelic
Composition
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Tg(GFP/KRAS2/ALPP)1Brn/0
Genetic
Background
involves: 129P2/OlaHsd * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Tg(GFP/KRAS2/ALPP)1Brn mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• upon induction with 4-hydroxytamoxifen (4-OHTA), 2/4 mice develop regional keratoacanthomas at site of drug application within 8 weeks
• 2/4 induced animals acquire lymphoma
• 2/4 induced animals acquire lung tumors

integument
• upon induction with 4-hydroxytamoxifen (4-OHTA), 2/4 mice develop regional keratoacanthomas at site of drug application within 8 weeks

respiratory system
• 2/4 induced animals acquire lung tumors





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory